Ex Vivo News and Research

RSS

Combining photoimmunotherapy and gene transduction effective against elusive gastric cancer cells

Researchers report photoimmunotherapy to be effective against elusive gastric cancer cells following transduction with the gene that expresses the extracellular domain protein of HER2. The results are published in the journal Small Molecule Therapeutics in February 2016.

15 Mar 2016

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with IgG4-Related Disease (IgG4-RD).

8 Mar 2016

SOM0226 (tolcapone) drug could significantly improve pharmacological treatment of ATTR

Researchers at the Institute of Biotechnology and Biomedicine, Universitat Autònoma de Barcelona (IBB-UAB), in collaboration with the biopharmaceutical company SOM Biotech, located in the Barcelona Science Park (PCB), have published, in Nature Communications, the results of a drug repositioning study in which they describe a powerful drug, SOM0226 (tolcapone) that could significantly improve the pharmacological treatment of familial transthyretin amyloidosis (ATTR).

24 Feb 2016

FDA clears Sangamo BioSciences' SB-318 IND application for treatment of MPS I

Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug (IND) application for SB-318, a single treatment strategy intended to provide a life-long therapy for Mucopolysaccharidosis Type I (MPS I).

8 Feb 2016

Novel quantitative method may reduce or eliminate need for invasive biopsies

Scientists have identified a quantitative method to measure changes in biomarkers, which may reduce or eliminate the need for invasive biopsies. The method, described in the February 2016 issue of The FASEB Journal uses a novel chimera design of DNA and small DNA with a companion contrast agent to allow antibodies to cross cellular membranes.

8 Feb 2016

Molecular imaging and radiochemistry: the importance of instrumentation. An interview with Professor Björn Wängler

Interview conducted with Professor Björn Wängler, Professor for Molecular Imaging and Radiochemistry from Heidelberg University.

From Bruker BioSpin Division 4 Feb 2016

Combined MRI and ultramicroscopy toolkit could help study vessel growth in glioma models in more detail

Stopping the growth of blood vessels in tumours is a key target for glioblastoma therapies, and imaging methods are essential for initial diagnosis and monitoring the effects of treatments. While mapping vessels in tumours has proven a challenge, researchers have now developed a combined magnetic resonance imaging (MRI) and ultramicroscopy 'toolkit' to study vessel growth in glioma models in more detail than previously possible.

3 Feb 2016

New $8.5M research grant aims to address patients affected by severe hemophilia A

People with hemophilia have prolonged abnormal bleeding as a result of trauma. Hemophilia A, also called factor VIII (FVIII) deficiency, is the most common form of the genetic disorder caused by missing or defective blood clotting protein called factor VIII.

23 Dec 2015

Sangamo presents Phase 2 data from two ongoing clinical trials of SB-728-T for treatment of HIV/AIDS

Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced the presentation of Phase 2 data from two of the Company's ongoing clinical trials (SB-728-1101 Cohort 3* and SB-728-mR-1401) of SB-728-T, which is being developed for the functional control of HIV/AIDS.

11 Dec 2015

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

New research adds to a growing body of evidence that gene therapy, an experimental technique that involves correcting or replacing a person's mutated or malfunctioning genes, may improve health outcomes for patients with inherited bleeding and immune disorders as well as some forms of blood cancer.

7 Dec 2015

New technique improves accuracy of CRISPR/Cas9 gene editing system

A new CRISPR/Cas9 technology developed by scientists at the University of Massachusetts Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.

19 Nov 2015

Confocal microscope designed specifically for scientists launched by Caliber ID

Caliber Imaging & Diagnostics, Inc. (Caliber I.D.), an Andover, MA-based medical technologies company with more than 20 years of experience in the design and development of innovative imaging solutions for the examination of tissue at the cellular level, has introduced its first confocal microscope exclusively for the research scientist, the RS-G4.

21 Oct 2015

Beta-catenin shows treatment target potential for TKI-resistant CML

Nuclear β-catenin could be a treatment target for patients whose chronic myeloid leukaemia is resistant to tyrosine kinase inhibitors independent of additional BCR–BL1 mutations, US researchers suggest.

1 Oct 2015

AMO Pharma raises $25 million in private equity financing

AMO Pharma Limited, a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, announced today that the company has raised $25 million in private equity financing from Woodford Investment Management.

30 Sep 2015

Researchers develop 3D bone marrow that produces functional human platelets ex vivo

Researchers funded by the National Institute of Biomedical Imaging and Bioengineering at Tufts University and their collaborators have successfully developed a 3-dimensional (3D) tissue-engineered model of bone marrow that can produce functional human platelets outside the body (ex vivo).

16 Sep 2015

Ex-vivo lung perfusion technique can reduce risk of transplant rejection

University of Manchester researchers have used a new technique to recondition poorly functioning lungs and remove donor white blood cells in an attempt to increase the number of lungs available for transplant, and at the same time reduce the risk of acute rejection.

15 Sep 2015

Potential new treatment for sepsis and ARDS

Scientists at Queen's University Belfast are developing a potential revolutionary new treatment for Sepsis and Acute Respiratory Distress Syndrome (ARDS), which are among the leading causes of death in hospitalised patients in the UK.

3 Sep 2015

Resverlogix presents new data on RVX-208 orally active BET inhibitor at ESC Congress 2015

Resverlogix Corp. is pleased to announce that Dr. Norman Wong, chief scientific officer of Resverlogix Corp. presented new data at the European Society of Cardiology (ESC) Congress 2015 in a poster presentation titled: "RVX-208, an orally active BET inhibitor, lowers CVD risk by activities beyond raising ApoA-I/HDL."

31 Aug 2015

Scientists bridge gap between two separate pieces of embryonic mouse intestine

University of Manchester scientists have bridged a gap between two separate pieces of small intestine kept alive outside the body, in an advance which could have implications for surgery in human adults and babies.

25 Aug 2015

Alnylam presents positive Phase 1 ALN-AT3 trial results in hemophilia at ISTH 2015 Congress

Additional study results from 12 hemophilia A and B subjects demonstrated that subcutaneous administration of ALN-AT3 achieved potent and dose-dependent knockdown of AT of up to 86%. AT knockdown was highly durable, with effects lasting over two months after the last dose, supporting further evaluation of a once-monthly subcutaneous dose regimen.

24 Jun 2015